AI Article Synopsis
- Prostaglandin I2 (PGI2) has been shown to lower tumor metastasis by altering how blood vessels form in tumors, although its exact impact on endothelial cells and pericytes remains unclear.
- In this study, researchers used a mouse model with Lewis lung carcinoma to examine the effects of beraprost sodium (BPS), a PGI2 analog, over three weeks.
- Results indicated that BPS treatment significantly reduced the number and size of lung metastases and appeared to enhance the number of tumor-associated pericytes while improving conditions within the tumors.
Article Abstract
Prostaglandin I2 (PGI2) agonist has been reported to reduce tumor metastasis by modifying tumor angiogenesis; however, the mechanisms of how PGI2 affects the endothelial cells or pericytes in tumor vessel maturation are still unclear. The purpose of this study was to clarify the effects of PGI2 on tumor metastasis in a mouse lung metastasis model using Lewis lung carcinoma (LLC) cells. The mice were treated continuously with beraprost sodium (BPS), a PGI2 analog, for 3 weeks and then examined for lung metastases. The number and size of lung metastases were decreased significantly by BPS treatment. In addition, scanning electron microscopy and immunohistochemistry revealed that BPS increased the number of tumor‑associated pericytes and improved intratumor hypoxia. Collectively, this study suggests that BPS attenuated vascular functional maturation in metastatic tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.2014.2783 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!